Scientists have identified a potential biomarker for early diagnosis of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is characterized by the formation of dense interstitium of pancreatic stellate cells (PSC).

In the article, researchers conducted studies on patients with pancreatic ductal adenocarcinoma (PDAC), healthy volunteers, and patients with other pancreatic non-cancerous diseases, and measured the level of PTX3 in their blood samples.

Researcher Professor Hemant Kocher said that in clinical, computed tomography (CT scan) technology is usually used to diagnose pancreatic cancer.

In the article, the researchers analyzed the blood samples of 267 donors, including 140 samples from PDAC patients.

Through the analysis of clinical trial data, the researchers found that when pancreatic cancer is targeted alone, PTX3 does not seem to change during chemotherapy; however, when both cancer and stroma-targeted therapies are used at the same time, the level of PTX3 is There will be changes.

The results of this study indicate that PTX3 may be used as a sensitive and specific biomarker to help distinguish pancreatic cancer from non-cancerous diseases in the pancreas; the researchers hope that the relevant research results may provide directions for future prospective clinical trials In order to determine whether PTX3 can be effectively used as a clinical biomarker for early diagnosis of pancreatic cancer, or combined with other biomarkers to monitor the response to pancreatic cancer therapy

In summary, the results of this article show that PTX3 may be used as a hypothetical matrix-derived special biomarker for early diagnosis of PDAC, but later researchers still need to conduct prospective and larger multicenter cohort studies, and The availability of this potential biomarker will be further tested in clinical trials

Original source:

Goulart, MR, Watt, J.